News - Paladin Labs


Current filters:

Paladin Labs

Popular Filters

FDA approves Impavido to treat tropical disease leishmaniasis

FDA approves Impavido to treat tropical disease leishmaniasis


The US Food and Drug Administration yesterday approved Canada-headquartered Paladin Impavido (miltefosine)…

Endo Health SolutionsImpavidoNorth AmericaPaladin LabsPharmaceuticalRegulationUSA

US FDA delays approval of Paladin’s Impavido

US FDA delays approval of Paladin’s Impavido


Canada-based specialty pharmaceutical company Paladin Labs says that the US Food and Drug Administration…

ImpavidoNorth AmericaPaladin LabsPharmaceuticalRegulationTropical diseases

Endo to acquire Paladin Labs in $1.6 billion deal

Endo to acquire Paladin Labs in $1.6 billion deal


Shares of Endo Health Solutions leapt 29% to $56.22 by close of trading on November 5, after the company…

Endo Health SolutionsFinancialMergers & AcquisitionsPaladin LabsPharmaceutical

Paladin and Bioniche officially close debt refinancing and Urocidin licensing deals


Canadian companies Bioniche Life Sciences (TSX: BNC) and Paladin Labs (TSX: PLB) said on Friday (July…

Bioniche Life SciencesFinancialLicensingOncologyPaladin LabsPharmaceuticalUrocidin

Paladin Labs acquires Binotal rights in Latin America from Bayer


Canadian specialty pharma firm Paladin Labs (TSX: PLB) has signed an agreement with German drug major…

Antibiotics and Infectious diseasesBayerBinotalLicensingPaladin LabsPharmaceuticalSouth America

Paladin gets certain rights to Immuron’s Travelan in up to C$117 million deal


Melbourne, Australia-based Immuron (ASX: IMC) and Canada’s Paladin Labs (TSX: PLB) have signed a…

Gastro-intestinalsImmuronLicensingPaladin LabsPharmaceuticalRespiratory and PulmonaryTravelan

Valeant out-bids Paladin with C$76 million cash bid for Afexa


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has entered…

Afexa Life SciencesMergers & AcquisitionsPaladin LabsPharmaceuticalValeant Pharmaceuticals

Paladin Labs to buy troubled Labopharm in $20.6 million deal


Paladin Labs (TSX: PLB) has entered into a definitive agreement to acquire fellow Canadian drugmaker…

LabopharmMergers & AcquisitionsPaladin LabsPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top